Indicated for the treatment of adult patients with metastatic Non-Small Cell Lung Cancer (NSCLC): 🧬 Second-line: For patients whose disease has progressed on other EGFR TKI therapy and who have developed the T790M mutation (confirmed by test). 🚀 First-line: As an initial treatment for patients with common EGFR mutations (Exon 19 deletion or Exon 21 L858R).

Dosage and administration

Standard Dosage: One 80 mg tablet once daily. ⚠️ Administration Instructions: Take at the same time each day, with or without food. Difficulty Swallowing? The tablet can be dispersed in 50 mL of non-carbonated water. Do not crush. Stir until dispersed and drink immediately. Rinse the glass with more water and drink to ensure the full dose is taken. 🚫 Interaction Warning: Avoid St. John's Wort and strong CYP3A inducers.

Pregnancy and breastfeeding (embryo-fetal toxicity). History of QTc interval prolongation (heart rhythm issues). Hypersensitivity to the active substance.

Generally better tolerated than 1st generation TKIs, but monitor for: Cardiac Issues: Decreased Left Ventricular Ejection Fraction (LVEF) or QTc prolongation. Skin & Nails: Rash, dry skin, paronychia (nail infections). Pulmonary: Interstitial Lung Disease (ILD)/Pneumonitis (rare but serious). Diarrhea.

Osimert — Osimertinib 80 mg, 30 pcs, Everest

100% original product

Active ingredient

Osimertinib

Manufacturer

Everest

Dosage 80 mg

Dosage form Tablets

Tablets per pack 30

Osimert (Osimertinib) 80 mg

Name: Osimert
Brand: Everest
SKU: PROD-91
Price: 7911 UAH
Availability: InStock

7911₴ ~~9669₴~~ -18%

Osimert (Osimertinib 80 mg) is a third-generation EGFR tyrosine kinase inhibitor (TKI), representing the most advanced standard of care for lung cancer.

Manufacturer: Everest Pharmaceuticals. A generic equivalent of Tagrisso.

The "Resistance Breaker":

Osimertinib is specifically designed to target both the initial EGFR mutation and the acquired T790M resistance mutation. It works when older drugs (like Gefitinib or Erlotinib) stop working.

✅ Key Benefit (CNS Activity): Unlike its predecessors, Osimert has high penetration into the brain, making it highly effective against CNS metastases.

Indicated for the treatment of adult patients with metastatic Non-Small Cell Lung Cancer (NSCLC):

🧬 Second-line: For patients whose disease has progressed on other EGFR TKI therapy and who have developed the T790M mutation (confirmed by test).
🚀 First-line: As an initial treatment for patients with common EGFR mutations (Exon 19 deletion or Exon 21 L858R).

Standard Dosage: One 80 mg tablet once daily.

⚠️ Administration Instructions:

Take at the same time each day, with or without food.
Difficulty Swallowing? The tablet can be dispersed in 50 mL of non-carbonated water. Do not crush. Stir until dispersed and drink immediately. Rinse the glass with more water and drink to ensure the full dose is taken.

🚫 Interaction Warning: Avoid St. John's Wort and strong CYP3A inducers.

Pregnancy and breastfeeding (embryo-fetal toxicity).
History of QTc interval prolongation (heart rhythm issues).
Hypersensitivity to the active substance.

Generally better tolerated than 1st generation TKIs, but monitor for:

Cardiac Issues: Decreased Left Ventricular Ejection Fraction (LVEF) or QTc prolongation.
Skin & Nails: Rash, dry skin, paronychia (nail infections).
Pulmonary: Interstitial Lung Disease (ILD)/Pneumonitis (rare but serious).
Diarrhea.

Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 04.03.2026